OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy

OP0007 Changes in Gene Expression and Inflammatory Proteins in Systemic Juvenile Idiopathic Arthritis Patients on Canakinumab Therapy

Background Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA.1 Objectives To analyze gene expression and inf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.62
Hauptverfasser: Brachat, A., Grom, A., Wulffraat, N., Brunner, H., Quartier, P., Brik, R., McCann, L., Ozdogan, H., Rutkowska-Sak, L., Schneider, R., Gerloni, V., Harel, L., Terreri, M., Houghton, K., Joos, R., Kingsbury, D., Lopez-Benitez, J., Bek, S., Schumacher, M., Valentin, M., Gram, H., Abrams, K., Martini, A., Ruperto, N., Lovell, D., Nirmala, N.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA.1 Objectives To analyze gene expression and inflammatory proteins in blood of SJIA patients (pts) on CAN therapy.To identify biomarkers that predict clinical response to CAN treatment at baseline. Methods Inflammatory protein biomarkers (IL-6; IL-18) and gene expression profiles of active SJIA pts (aged 2 to
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2014-eular.2320